Breast Cancer | Specialty

Identifying Unmet Needs and Remaining Questions

October 3rd 2025

Panelists discuss how the rapidly evolving breast cancer treatment landscape includes promising developments in oral selective estrogen receptor degraders (SERDs), CDK4/6 inhibitor sequencing strategies, and antibody-drug conjugates (ADCs), with new targeted therapies and bispecifics continuing to emerge.

Dr LeVee on Selecting and Sequencing ADCs in Breast Cancer

October 2nd 2025

Alexis LeVee, MD, discusses how clinical trial design guides the practical application of data for ADC selection in breast cancer.

OncLive’s September EMA Regulatory Recap: Key EU Approvals in Oncology

October 2nd 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in September 2025.

Treatment Options in the 2L for HER2-Low Disease Including ADCs and Endocrine Therapy

October 2nd 2025

Panelists discuss how treatment decisions between antibody-drug conjugates (ADCs) and continued endocrine-based therapies in HER2-low disease depend on endocrine sensitivity, with ADCs reserved for endocrine-refractory tumors or primary endocrine-resistant cases with short initial response durations.

Evaluating the ASCENT-04 Trial Results in Triple-Negative Disease

October 2nd 2025

Panelists discuss how the ASCENT-04 trial findings establish sacituzumab govitecan (SG)plus pembrolizumab as an active standard-of-care combination for triple-negative breast cancer, with considerations needed for patients with prior immunotherapy exposure.

FDA Grants Fast Track Designation to ETX-636 for PIK3CA-Mutant, HR+/HER2-Negative Breast Cancer

October 1st 2025

ETX-636, a selective PI3Kα inhibitor, has received FDA fast track designation for PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer.

FDA Accepts sBLA for T-DXd Followed by THP in High-Risk, HER2+ Early-Stage Breast Cancer

October 1st 2025

The FDA accepted an sBLA seeking the approval of neoadjuvant T-DXd followed by THP for the management of high-risk, HER2-positive breast cancer.

The Role of T-DXd in the Frontline Setting for HER2+ mBC and Treatment Personalization

October 1st 2025

Panelists discuss how DESTINY-Breast09 data support trastuzumab deruxtecan (T-DXd) plus pertuzumab in frontline HER2-positive disease for select patients with extensive disease or brain metastases while emphasizing individualized treatment decisions to avoid overtreatment.

CDK4/6 Inhibitor Sequencing in the Metastatic Setting and Maintenance Strategies Following THP Induction

October 1st 2025

Panelists discuss how prior adjuvant CDK4/6 inhibitor exposure complicates metastatic treatment decisions, with limited data supporting rechallenge strategies and the need for more targeted therapies such as CDK2- or CDK4-specific inhibitors.

FDA Approves 2 Biosimilars for Osteoporosis and Cancer-Related Bone Disease

September 30th 2025

The FDA approved Enoby and Xtrenbo, denosumab biosimilars referencing Prolia and Xgeva, respectively.

Northwell Cancer Institute Unveils $14M Center for Women's Cancer, Creating an Integrated Care Model With Comprehensive Services in One Location

September 30th 2025

The Northwell Cancer Institute unveiled its Center for Women's Cancer at the R.J. Zuckerberg Cancer Center.

Orphan Drug Designation Sought for Crofelemer to Manage Treatment-Related Diarrhea in Breast Cancer With Brain Metastases

September 29th 2025

Crofelemer may receive ODD for diarrhea treatment in patients with breast cancer and brain metastases receiving targeted therapy with/without chemotherapy.

Poll: Vote on the Top Breast Cancer, Hematology Abstracts to Watch at ESMO 2025

September 29th 2025

FDA Clears Guardant360 CDx as Companion Diagnostic for Imlunestrant in ESR1-Mutated Breast Cancer

September 29th 2025

The Guardant360 CDx liquid biopsy test has been approved to identify patients with ESR1-mutated breast cancer who are eligible to receive imlunestrant.

Five Under 5: Top Oncology Videos for the Week of 9/21

September 28th 2025

The top 5 OncLive TV videos of the week cover insights in solid tumors, breast cancer, pancreatic cancer, and multiple myeloma.

The OncFive: Top Oncology Articles for the Week of 9/21

September 27th 2025

Imlunestrant joins the treatment arsenal for ESR1-mutated metastatic breast cancer, T-DXd doublet gets priority review in HER2+ breast cancer, and more.

Dr Meisel on the Mechanism of Action of Palazestrant in ER+, HER2– Breast Cancer

September 26th 2025

Jane L. Meisel, MD, FASCO, discusses the mechanism of action of palazestrant in ER+, HER2– advanced/metastatic breast cancer.

FDA Approves Imlunestrant for ER+, HER2-Negative, ESR1-Mutated Metastatic Breast Cancer

September 25th 2025

The FDA approved imlunestrant for ER-positive, HER2-negative advanced or metastatic ESR1-mutated breast cancer following endocrine therapy.

Breast Cancer Experts: Key ADC Developments and CDK 4/6 Inhibitor Updates Set to Dominate ESMO 2025

September 25th 2025

Ahead of the 2025 ESMO Congress, breast cancer experts share the most anticipated research being presented during the meeting.

CDK4/6 Inhibitor Combination Therapy in HER2+ Disease

September 24th 2025

Panelists discuss how the PATINA trial findings demonstrate significant progression-free survival benefit from adding palbociclib to endocrine and HER2-targeted therapy in patients with estrogen receptor (ER)–positive, HER2-positive disease following induction chemotherapy, though access challenges remain in clinical practice.